Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) has announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 p.m. ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days post-event.

Praxis focuses on developing therapies for central nervous system (CNS) disorders that stem from neuronal excitation-inhibition imbalances. The company utilizes its proprietary platforms, Cerebrum™ and Solidus™, to leverage genetic insights for creating therapies for rare and prevalent neurological conditions. With a diverse portfolio, Praxis has multiple clinical-stage product candidates targeting movement disorders and epilepsy.

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22^nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.

The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

FAQ

When will Praxis present at the Needham Virtual Healthcare Conference?

Praxis will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 p.m. ET.

How can I access the live webcast of the Praxis conference presentation?

The live webcast of the Praxis conference presentation can be accessed through the Events & Presentations page on the company's website.

Will there be a replay of the Praxis conference presentation available?

Yes, a replay of the Praxis conference presentation will be available on the company's website for 90 days following the event.

What is the focus of Praxis Precision Medicines?

Praxis Precision Medicines focuses on developing therapies for central nervous system disorders caused by neuronal excitation-inhibition imbalances.

What platforms does Praxis use for therapy development?

Praxis utilizes its proprietary platforms, Cerebrum™ and Solidus™, to develop therapies based on genetic insights.